Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Sarah A. Washkowitz"'
Autor:
Aditya Bardia, Steven J. Isakoff, Sarah A. Washkowitz, Hope S. Rugo, Ingrid A. Mayer, Linda T. Vahdat, Ala M Sweidan, William A. Wegener, Alessandro D. Santin, Joyce O'Shaughnessy, Nikita C. Shah, Kevin Kalinsky, Sara M. Tolaney, Rebecca L. Moroose, Vandana G. Abramson, Jennifer R. Diamond, David M. Goldenberg, Robert Iannone, Robert M. Sharkey
Publikováno v:
New England Journal of Medicine. 380:741-751
Standard chemotherapy is associated with low response rates and short progression-free survival among patients with pretreated metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ac67a01c658a493abb0e34b2b312cdd
https://doi.org/10.1056/nejmoa1814213
https://doi.org/10.1056/nejmoa1814213
Autor:
William A. Wegener, Linda T. Vahdat, Dejan Juric, Rebecca L. Moroose, Sara M. Tolaney, Jennifer R. Diamond, David M. Goldenberg, Kevin Kalinsky, Ingrid A. Mayer, Robert M. Sharkey, Joyce O'Shaughnessy, Vandana G. Abramson, Sarah A. Washkowitz, Aditya Bardia
Publikováno v:
Journal of Clinical Oncology. 36:1004-1004
1004Background: Sacituzumab govitecan is a novel antibody-drug conjugate consisting of SN-38, the active metabolite of irinotecan, conjugated to a humanized mAb targeting Trop-2 (trophoblastic anti...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb385f9d89b7507ff4646bdb1bcaafd5
https://doi.org/10.1200/jco.2018.36.15_suppl.1004
https://doi.org/10.1200/jco.2018.36.15_suppl.1004